In phase III CodeBreak 200 trial presented by Dr. Melissa Johnson, oral #sotorasib demonstrated superior PFS and ORR compared to docetaxel in #NSCLC patients with #KRASG12C mutation after progression on prior platinum based chemotherapy and IO. In this first randomized phase III trial, #sotorasib showed a 34% improvement in the PFS (HR 0.66, P=0.002) Vs docetaxel. Additionally, sotorasib significantly improved the ORR (28.1% Vs 13.2%). The study wasn’t powered to detect OS improvement and crossover was allowed between the two arms upon progression.